Hormonal
FFAR3 (GPR41) is dispensable for normal body weight, adiposity, and glucose homeostasis in mice, and is not required for the obesity-protective effects of butyrate and propionate.
The receptor FFAR3 (GPR41) is not required for maintaining normal body weight, fat levels, or blood sugar control in mice. This suggests that other mechanisms can compensate for its absence, and that therapies targeting FFAR3 might not be strictly necessary for basic metabolic health.
Ffar3 knockout mice showed no significant difference in body weight compared to wild-type littermates on standard chow diet and after one week of HFD feeding... Ffar3 knockout mice maintained on HFD showed normal glycemia... oral glucose tolerance... and insulin tolerance... These data suggest that FFAR3 is dispensable for normal energy homeostasis and glucose metabolism.
Why this rating
The use of a knockout model provides definitive evidence that the receptor is not required for the observed outcomes.
Source
Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms
Hua Lin et al. · PLoS ONE · 2012
DOI 10.1371/journal.pone.0035240
More from this paper
- Dietary supplementation with butyrate and propionate protects against diet-induced obesity and improves glucose tolerance in mice, with butyrate and propionate also reducing food intake via FFAR3-independent mechanisms.Good
- Butyrate and propionate acutely stimulate the secretion of gut hormones (GLP-1, GIP, PYY) in mice, with butyrate being the most potent stimulator of anorexigenic peptides.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →